皓宸医疗(002622) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥39,877,498.75, representing a 47.65% increase compared to ¥27,008,944.61 in the same period last year[8]. - The net profit attributable to shareholders was -¥9,581,679.68, a decrease of 15.26% from -¥8,312,871.88 year-on-year[8]. - The basic earnings per share for the period was -¥0.0114, a decrease of 15.15% from -¥0.0099 in the same period last year[8]. - The company reported a net profit loss of ¥9,032,379.56 for Q1 2019, compared to a loss of ¥4,729,248.60 in the same period last year, indicating a year-over-year increase in losses of approximately 91.5%[45]. - The total comprehensive income for the current period was -¥9,032,379.56, compared to -¥4,729,248.60 in the previous year, marking an increase in comprehensive losses of about 91.5%[46]. Cash Flow - The net cash flow from operating activities was -¥12,743,347.22, a significant decline of 188.19% compared to ¥14,450,282.39 in the previous year[8]. - Cash flow from operating activities included cash received from sales of goods and services amounting to ¥44,784,625.47, compared to ¥25,294,406.94 in the previous period, indicating a significant increase of approximately 77.1%[51]. - The total cash inflow from operating activities was 59,454,919.50 CNY, while total cash outflow was 72,198,266.72 CNY, leading to a net cash flow from operating activities of -12,743,347.22 CNY[52]. - The ending balance of cash and cash equivalents is ¥46,344,992.08, a decrease of 53.56% compared to the end of the previous year, due to debt repayment, investment in financial products, and net cash outflow from operations[16]. - The cash outflow for paying dividends and interest was 8,388,977.53 CNY, slightly lower than 8,747,064.84 CNY in the previous period[53]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,834,857,868.33, down 1.94% from ¥1,871,234,376.91 at the end of the previous year[8]. - The company's current assets totaled CNY 502,717,752.43, down from CNY 548,477,566.83 at the end of 2018, indicating a decline of approximately 8.6%[35]. - Total liabilities decreased to CNY 843,052,194.31 from CNY 855,865,989.57 at the end of 2018, reflecting a reduction in financial obligations[42]. - Current liabilities reached CNY 848,234,072.86, including short-term borrowings of CNY 130,000,000.00[63]. - The company's total liabilities increased, impacting its cash flow and financial stability, although specific figures were not detailed in the provided content[58]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 56,542[12]. - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, held 23.81% of the shares, totaling 200,000,000 shares[12]. - The company has a total of CNY 1,280,529,058.29 in equity attributable to shareholders of the parent company[61]. Research and Development - R&D expenses for the period are ¥2,685,227.11, reflecting a 30.33% increase year-on-year as the company intensifies its R&D efforts[16]. - Research and development expenses for Q1 2019 were CNY 2,685,227.11, up from CNY 2,060,268.43 in Q1 2018, indicating an increased focus on innovation[43]. Strategic Initiatives - The company has signed a cooperation framework agreement with Alibaba Group, focusing on e-commerce, new retail, big data, and AI solutions, although formal agreements are still pending[17]. - The company plans to transfer 100% equity of Zhongyuan Hengxin Industrial Group to optimize its asset structure and support its main business upgrade[20]. - The company has not yet signed formal agreements for further cooperation with Alibaba, indicating that the collaboration is still in the preliminary stages[17]. Other Financial Metrics - The company reported non-recurring gains and losses totaling ¥941,808.61, primarily from the disposal of obsolete inventory and government subsidies[9]. - The company incurred management expenses of ¥8,594,276.56, down from ¥11,001,518.69 in the previous period, showing a reduction of approximately 21.9%[47]. - Financial expenses totaled ¥6,894,546.74, a decrease from ¥8,219,665.63 in the previous year, reflecting a reduction of about 16.1%[47]. - The company recorded an investment income of ¥13,114,006.03, compared to ¥12,900,921.58 in the previous year, indicating a slight increase of approximately 1.7%[48].